Literature DB >> 25350468

Cardiogenic shock after use of fluoroamphetamine confirmed with serum and urine levels.

Suad Al-Abri1, Kathryn H Meier, Jennifer M Colby, Craig G Smollin, Neal L Benowitz.   

Abstract

CONTEXT: 4-Fluoroamphetamine (4-FA) is a para-substituted phenethylamine-type synthetic stimulant that has in recent years gained popularity through internet blogs and market share according to confiscated drug data. No serious toxicity has previously been reported. We report a case of a young man who developed severe toxicity and cardiogenic shock after using 4-FA, with laboratory confirmation. CASE DETAILS: An 18-year-old man presented to the emergency department with vomiting, shortness of breath, chest tightness, and altered mental status about 5 h after using a new and unfamiliar street drug. Two days prior, he had received naltrexone intramuscular injection as part of an opioid addiction treatment program and was taking fluoxetine and trazodone. Five hours after presentation, he developed cardiogenic shock requiring intraaortic balloon pump, inotropic and ventilatory support. An echocardiogram showed left ventricular (LV) hypokinesia, sparing the apex and ejection fraction (EF) = 10%. Comprehensive toxicology serum testing revealed FA, naproxen, trazodone, and cotinine. The 4-FA urine level was 64,000 ng/ml and serum level was 118 ng/ml. With slow recovery, the patient was discharged after 2 weeks of hospitalization. DISCUSSION: Although no previously reported 4-FA clinical poisoning cases have been published for comparison, by examining 4-FA pharmacology compared with other stimulant drugs, and given this patient's presentation and echocardiogram suggestive of reverse takotsubo cardiomyopathy we suspect the toxic mechanism was an acute cardiomyopathy caused by 4-FA catecholamine-induced myocarditis and/or small vessel myocardial ischemia.
CONCLUSION: Recreational use of 4-FA may present with life threatening toxicity including cardiomyopathy, cardiogenic shock, and pulmonary edema.

Entities:  

Keywords:  Cardiogenic shock; Designer drugs; Fluroamphetamine; Laboratory analysis; Reverse takotsubo cardiomyopathy

Mesh:

Substances:

Year:  2014        PMID: 25350468     DOI: 10.3109/15563650.2014.974262

Source DB:  PubMed          Journal:  Clin Toxicol (Phila)        ISSN: 1556-3650            Impact factor:   4.467


  6 in total

1.  4-Fluoroamphetamine in Serum and Urine from an Intoxicated Patient with Life-Threatening Hyperpyrexia.

Authors:  Justin L Poklis; Carl E Wolf; Alphonse Poklis
Journal:  J Anal Toxicol       Date:  2016-01-18       Impact factor: 3.367

Review 2.  Haemorrhagic stroke related to the use of 4-fluoroamphetamine.

Authors:  C H W Wijers; M C Visser; R T H van Litsenburg; R J M Niesink; R B Willemse; Esther A Croes
Journal:  J Neurol       Date:  2018-05-08       Impact factor: 4.849

3.  Acute dilated cardiomyopathy and myocardial injury after combined 4-fluoroamphetamine and modafinil ingestion.

Authors:  Carl E Wolf; Justin L Poklis; Kirk Cumpston; Michael Moss; Alphonse Poklis
Journal:  Drug Test Anal       Date:  2016-05-30       Impact factor: 3.345

4.  Reverse Takotsubo Cardiomyopathy Precipitated by Chronic Cocaine and Cannabis Use.

Authors:  Emily Nash; Darren M Roberts; Nazila Jamshidi
Journal:  Cardiovasc Toxicol       Date:  2021-08-24       Impact factor: 3.231

5.  Acute onset heart failure due to reverse type Takotsubo cardiomyopathy caused by a single dose of 4-Fluoroamphetamine in a healthy young individual.

Authors:  R S D van der Pas; F M J Gresnigt; L Wansink; E J F Franssen; R K Riezebos
Journal:  Toxicol Rep       Date:  2020-12-03

6.  4-Fluoroamphetamine (4-FA) intoxication results in exaggerated blood pressure effects compared to MDMA and amphetamine: A retrospective analysis.

Authors:  Femke M J Gresnigt; Anouk Snik; Eric J F Franssen; Joost W Vanhommerig; Dylan W de Lange; Robert K Riezebos
Journal:  J Am Coll Emerg Physicians Open       Date:  2022-09-26
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.